Peptide News Digest

FDA PCAC Feb 2027: 5 More Peptides (LL-37, GHK-Cu, Melanotan II), Novo -5% on Pill Economics, Q2 Big-Pharma Earnings Wrap

FDA PCAC schedules Feb 2027 review of 5 more peptides (LL-37, GHK-Cu, dihexa, MT-II, PEG-MGF). Novo -5% on Wegovy pill economics. Q2 big-pharma wrap.

4 stories · Covering regulatory, industry

Editor's Note

Thursday's peptide news pivots from earnings-print week to two substantive follow-through stories. First, the FDA's Pharmacy Compounding Advisory Committee (PCAC) has scheduled a second peptide meeting before the end of February 2027 to review five additional peptides: cathelicidin (LL-37, antimicrobial peptide), GHK-Cu (copper tripeptide cosmetic peptide), dihexa acetate (nootropic), melanotan II (skin pigmentation and appetite-suppression peptide), and pegylated mechano growth factor (PEG-MGF, muscle repair). The February 2027 review continues the July 23-24 PCAC session that recommended 6 of 7 peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) for Section 503A Bulks List inclusion. Second, Novo Nordisk shares fell approximately 5% Tuesday-Wednesday as CEO Lars Fruergaard Jorgensen defended Wegovy pill economics on the H1 2026 earnings call, with investors concerned about the low-price environment from Most-Favored-Nation pricing deals and the Medicare GLP-1 Bridge Program that both compress branded GLP-1 margins even as prescription volume climbs. Wegovy pill (oral semaglutide 25/50 mg) has reached more than 5 million cumulative prescriptions since Q1 2026 launch. On the broader peptide-and-obesity industry earnings picture, Q2 2026 delivered mixed signals: Merck beat and raised revenue guidance but cut adjusted EPS on the $5.7B Terns Pharmaceuticals charge, Pfizer beat and raised guidance midpoint, Amgen beat and killed AMG 513 obesity candidate, Eli Lilly delivered a $23 billion blowout (+48%) with Foundayo's first commercial-quarter view at $98 million, Novo raised H1 guidance but shares fell on margin concerns, and Alnylam extended a 30% selloff since Q2. BioMarin (NASDAQ: BMRN) reports Q2 2026 earnings tonight after market close.

Regulatory

FDA Pharmacy Compounding Advisory Committee (PCAC) Has Scheduled a Second Peptide Meeting Before the End of February 2027 to Review Five Additional Peptides for Section 503A Bulks List Inclusion Following the July 23-24, 2026 Session That Recommended 6 of 7 Peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon; DSIP Rejected); The February 2027 Docket Covers Cathelicidin (LL-37, Antimicrobial Peptide With Broad Anti-Infective and Immune-Modulatory Activity), GHK-Cu (Copper Tripeptide Widely Marketed in Cosmetic and Wound-Healing Formulations), Dihexa Acetate (Angiotensin-Derived Nootropic), Melanotan II (α-MSH Analog for Skin Pigmentation and Appetite Suppression), and Pegylated Mechano Growth Factor (PEG-MGF, Muscle Repair Peptide)

The FDA Pharmacy Compounding Advisory Committee (PCAC) has scheduled a second peptide meeting before the end of February 2027 to review five additional peptides for Section 503A Bulks List inclusion. The February 2027 docket covers: cathelicidin (LL-37), a broad-spectrum antimicrobial peptide with anti-infective and immune-modulatory activity; GHK-Cu (glycyl-histidyl-lysine copper tripeptide), a widely-marketed cosmetic and wound-healing peptide previously in FDA Category 2; dihexa acetate, an angiotensin IV-derived nootropic that has been marketed for cognitive enhancement; melanotan II, an alpha-melanocyte-stimulating hormone analog marketed for skin pigmentation (self-tanning) and appetite suppression; and pegylated mechano growth factor (PEG-MGF), a muscle-repair peptide derived from insulin-like growth factor 1 splice variants. The February 2027 review continues the July 23-24, 2026 PCAC session that recommended 6 of 7 peptides for Section 503A Bulks List inclusion (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon approved; Emideltide/DSIP rejected). FDA has not yet posted the final date and public-comment docket details for the February 2027 meeting. Under standard rulemaking timelines, the FDA's process of Notice of Proposed Rulemaking, public comment period, and final rule after any positive PCAC recommendation takes 12-24 months.

#pcac #fda #february-2027-meeting #cathelicidin #ll-37 #ghk-cu #dihexa-acetate #melanotan-ii #peg-mgf #mechano-growth-factor #antimicrobial-peptide #cosmetic-peptide #503a-bulks-list
Industry

Novo Nordisk (NYSE: NVO) Shares Fell Approximately 5% Tuesday-Wednesday Following the August 4 H1 2026 Earnings Release as CEO Lars Fruergaard Jorgensen Defended Wegovy Pill Economics on the Earnings Call While Analysts Focus on the Compressed Margin Trajectory From the Most-Favored-Nation Pricing Deals With the Trump Administration (November 2025) and the Medicare GLP-1 Bridge Program (Launched July 1) That Both Reduce Net Realized Prices Per Unit Even as Prescription Volume Climbs; Wegovy Pill Has Reached More Than 5 Million Cumulative US Prescriptions Since Q1 2026 Launch

Novo Nordisk (NYSE: NVO) shares fell approximately 5% across Tuesday and Wednesday August 4-5, 2026 following the H1 2026 earnings release. CEO Lars Fruergaard Jorgensen defended Wegovy pill economics on the earnings call, addressing analyst concerns about the compressed margin trajectory from the Most-Favored-Nation pricing deals announced with the Trump administration in November 2025 (which paired lower drug prices with expanded Medicare access and a three-year tariff grace period) and the Medicare GLP-1 Bridge Program launched July 1, 2026 (providing Wegovy, Zepbound KwikPen, and Foundayo at a capped $50/month copay for eligible Medicare Part D beneficiaries through December 31, 2027). Both programs reduce net realized prices per unit even as prescription volume climbs. Wegovy pill (oral semaglutide 25/50 mg for obesity) has reached more than 5 million cumulative US prescriptions since the Q1 2026 launch, one of the fastest oral obesity-drug uptake curves on record. Novo Nordisk H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion, +3% constant currency); the company raised full-year 2026 guidance from prior expectations to down 6% to flat at constant exchange rates. Analyst attention now focuses on 2027 pricing environment and Novo's ability to defend franchise economics as Eli Lilly's tirzepatide and orforglipron continue to widen the competitive gap.

#novo-nordisk #nvo #wegovy-pill #oral-semaglutide #5-million-prescriptions #mfn-pricing #medicare-glp-1-bridge #margin-compression #eli-lilly #competitive-gap
Industry

Q2 2026 Peptide-and-Obesity Earnings Week Wrap: Merck (MRK) $16.61B Revenue Beat + Raised Guidance With LIPFENDRA Launch Focus and $5.7B Terns Acquisition Charge; Pfizer (PFE) $15B Revenue Beat + Raised Guidance With Obesity Program Momentum; Amgen (AMGN) $10.05B Revenue Beat + Raised Guidance and Discontinued AMG 513 Early-Stage Obesity Candidate Leaving MariTide as Sole Focus; Eli Lilly (LLY) $23B Revenue (+48%) Blowout + Raised Guidance to $85-87B With Foundayo $98M First Commercial Quarter; Novo Nordisk (NVO) H1 78.49B DKK ($12.09B) + Raised Guidance but Shares -5% on Margin Concerns; Alnylam (ALNY) Extends 30% Selloff on Amvuttra Guidance Cut + Eplontersen Setback

The peptide-and-obesity Q2 2026 earnings week (Merck August 4, Pfizer August 4, Amgen August 4, Eli Lilly August 5, Novo Nordisk H1 August 4-5) delivered mixed signals across the pharma sector. Merck (NYSE: MRK) posted $16.61 billion Q2 revenue (+5% YoY, beat consensus by $250M), raised FY revenue guidance to $66.3-67.3 billion but cut adjusted EPS guidance to $2.66-2.76 due to a $5.7 billion Terns Pharmaceuticals acquisition charge; Keytruda reached $8.37 billion (+5%) and LIPFENDRA (enlicitide) launched at $315/month with $5 billion peak sales potential by 2034. Pfizer (NYSE: PFE) reported $15 billion revenue and $0.77 adjusted diluted EPS, raised FY revenue guidance midpoint to $60.5-62.5 billion, and CEO Bourla said the obesity program (danuglipron plus Metsera pipeline) is advancing with substantial momentum. Amgen (NASDAQ: AMGN) reported $10.05 billion Q2 revenue (+10% YoY), raised FY guidance to $38.2-39.4 billion, discontinued AMG 513 early-stage obesity candidate leaving MariTide as sole obesity focus. Eli Lilly (NYSE: LLY) delivered $23 billion Q2 revenue (+48% YoY blowout), raised FY guidance to $85-87 billion, Mounjaro reached $9.9 billion (+91%), Zepbound $4.9 billion US (+44%), and Foundayo generated $98 million in first fully operational commercial quarter. Novo Nordisk H1 reached 78.49 billion DKK ($12.09 billion, +3% CER) with Wegovy pill at 5 million+ prescriptions and raised guidance; NVO shares fell 5% on margin concerns. Alnylam (NASDAQ: ALNY) extended a 30% selloff (approximately $12 billion market cap lost) since the July 30 Q2 report on the Amvuttra TTR guidance cut plus eplontersen setback.

#q2-2026-earnings #earnings-wrap #merck #pfizer #amgen #eli-lilly #novo-nordisk #alnylam #lipfendra #foundayo #wegovy-pill #mounjaro #zepbound #maritide #amvuttra
Industry

BioMarin Pharmaceutical (NASDAQ: BMRN) Hosts Q2 2026 Financial Results Conference Call and Webcast Thursday August 6 at 4:30 PM ET Alongside Amylyx Pharmaceuticals (NASDAQ: AMLX) and Tarsus Pharmaceuticals (NASDAQ: TARS) Reporting Thursday Morning; BioMarin Focus on Voxzogo (Vosoritide, C-Type Natriuretic Peptide Analog for Achondroplasia) Commercial Trajectory, ROCTAVIAN (Valoctocogene Roxaparvovec Hemophilia A Gene Therapy), Palynziq for Phenylketonuria, and the Broader Rare-Disease Enzyme Replacement Franchise That Includes VIMIZIM, Naglazyme, and Aldurazyme

BioMarin Pharmaceutical (NASDAQ: BMRN) hosts its Q2 2026 financial results conference call and webcast Thursday August 6, 2026 at 4:30 PM ET. Analyst focus areas: Voxzogo (vosoritide) commercial trajectory in achondroplasia (Voxzogo is a C-type natriuretic peptide analog administered by daily subcutaneous injection, making it a substantive peptide franchise for the site's coverage); ROCTAVIAN (valoctocogene roxaparvovec) hemophilia A AAV gene therapy commercial ramp and payer coverage; Palynziq (pegvaliase-pqpz) for phenylketonuria (PKU) revenue trajectory; and the broader rare-disease enzyme replacement franchise including VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), and Aldurazyme (laronidase). BioMarin has been transitioning its commercial focus from the mature enzyme replacement franchise toward newer growth drivers (Voxzogo and ROCTAVIAN) with analyst attention on the balance of growth-portfolio contribution versus legacy-franchise stability. Amylyx Pharmaceuticals (NASDAQ: AMLX) also reports Q2 2026 results Thursday August 6 at 8:00 AM ET, with focus on the amyotrophic lateral sclerosis (ALS) pipeline following the March 2024 US withdrawal of Relyvrio and pipeline reprioritization to progressive supranuclear palsy (PSP) and other rare neurodegenerative indications. Tarsus Pharmaceuticals (NASDAQ: TARS) reports at 8:00 AM ET.

#biomarin #bmrn #voxzogo #vosoritide #roctavian #palynziq #amylyx #amlx #tarsus #tars #achondroplasia #hemophilia-a #phenylketonuria #q2-2026-earnings